Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer
MADRID — Chemotherapy’s generation-long dominance in first-line advanced urothelial cancer ended with a resounding victory for the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) in an international randomized trial. Overall survival (OS) and progression-free survival (PFS) doubled with enfortumab-pembrolizumab (EV-P) at 12.5 and 31.5 months versus 6.3 and 16.1 months with platinum-containing chemotherapy. […]
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO — Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived significantly longer if they received the selective FGFR inhibitor erdafitinib (Balversa) instead of chemotherapy, a randomized trial showed. Median overall survival (OS) increased from 7.8 months with physician’s choice of chemotherapy to 12.1 months with the targeted agent. Progression-free survival (PFS) […]
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer
PARIS — Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients responded to frontline enfortumab vedotin (EV; Padcev) and pembrolizumab (Keytruda), including eight complete responses. An additional 17 patients had stable disease, resulting in a clinical […]
PD-1 Inhibitor OK’d as Adjuvant Therapy for Bladder Cancer
The FDA has approved nivolumab (Opdivo) as an adjuvant therapy for patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement, or PD-L1 status, Bristol Myers Squibb announced. Nivolumab becomes the first PD-1 inhibitor in UC with an indication in the adjuvant […]